News
- Author:
- Sara Freeman
Publish date: April 30, 2013
Major finding: Revision surgery rates were 1.88% in bisphosphonate users vs.
News
- Author:
- Sara Freeman
Publish date: April 24, 2013
Major finding: At 12 months, HAQ scores were lower in patients treated with DMARDs than in patients treated with a TNF inhibitor (1.35 vs. 1.60; P...
News
- Author:
- Sara Freeman
Publish date: March 28, 2013
Major finding: The hazard ratio for death in patients with ERCC1-negative tumors was 1.16 (P = .62), and for ERCC1-positive tumors it was 0.78 (P ...
News
- Author:
- Sara Freeman
Publish date: March 27, 2013
Major finding: Pulmonary exacerbations occurred less frequently with erythromycin (1.29 vs. 1.97/patient per year, P = .003) or azithromycin (medi...
News
- Author:
- Sara Freeman
Publish date: March 25, 2013
Major finding: A 0.77-fold reduced risk of bladder cancer was associated with a single nucleotide polymorphism (rs10759) found on the RGS4 gene.Da...
News
- Author:
- Sara Freeman
Publish date: January 28, 2013
Major Finding: In 1971, 32% of 1,094 malignant melanomas registered in England occurred in men; in 2009, 48% of 9,771 registrations were in men.Da...
News
- Author:
- Sara Freeman
Publish date: November 21, 2012
News
- Author:
- Sara Freeman
Publish date: November 15, 2012
Major Finding: ADL worsened in 17.2% of elderly cancer patients, and IADL in 38.9%, and 17.5% experienced at least one fall.Data Source: Data are ...
News
- Author:
- Sara Freeman
Publish date: November 5, 2012
Major Finding: Crude 10-year incidences of multiple primary malignancy were 11.7, 16.7, 17.8, and 16.4/10,000 person-years for women younger than ...
News
- Author:
- Sara Freeman
Publish date: November 2, 2012
Major Finding: Older women were less likely to have tumors that were positive for Ki67 (48% vs. 87.7%) or p53 (44.6% vs.
News
- Author:
- Sara Freeman
Publish date: October 30, 2012
Major Findings: Median progression-free survival was 4.4 vs.
News
- Author:
- Sara Freeman
Publish date: October 18, 2012
Major Findings: The primary end point of CNS as first site of relapse was no different comparing lapatinib-capecitabine (3%) vs. trastuzumab-capec...
News
- Author:
- Sara Freeman
Publish date: October 17, 2012
Major Finding: Secondary end points of progression-free survival (HR 1.36, P = .005) and objective response rates (P less than .0001) were signifi...
News
- Author:
- Sara Freeman
Publish date: October 17, 2012
Major Findings: Half of all patients treated with a dual HER2 blockade and paclitaxel achieved a pathological complete response, but 58.6% went on...
News
- Author:
- Sara Freeman
Publish date: October 12, 2012
Major Findings: Median progression-free survival was 4.4 vs.
